Cargando…
Cost-effectiveness analysis of vaccination against COVID-19 in China
INTRODUCTION: Since September 2020, Chinese populations aged > 3 years have been encouraged to receive a two-dose inoculation with vaccines against coronavirus disease 2019 (COVID-19). This study aims to evaluate the cost-effectiveness of the current vaccination strategy amongst the general popul...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027744/ https://www.ncbi.nlm.nih.gov/pubmed/36960359 http://dx.doi.org/10.3389/fpubh.2023.1037556 |
_version_ | 1784909774807105536 |
---|---|
author | Zhou, Huixuan Ding, Ningxin Han, Xueyan Zhang, Hanyue Liu, Zeting Jia, Xiao Yu, Jingjing Zhang, Wei |
author_facet | Zhou, Huixuan Ding, Ningxin Han, Xueyan Zhang, Hanyue Liu, Zeting Jia, Xiao Yu, Jingjing Zhang, Wei |
author_sort | Zhou, Huixuan |
collection | PubMed |
description | INTRODUCTION: Since September 2020, Chinese populations aged > 3 years have been encouraged to receive a two-dose inoculation with vaccines against coronavirus disease 2019 (COVID-19). This study aims to evaluate the cost-effectiveness of the current vaccination strategy amongst the general population in mainland China from a societal perspective. METHODS: In this study, we construct a decision tree with Markov models to compare the economic and health consequences of the current vaccination strategy versus a no-vaccination scenario, over a time horizon of one year and an annual discount rate of 5%. Transition probabilities, health utilities, healthcare costs, and productivity losses are estimated from literature. Outcome measures include infection rates, death rates, quality-adjusted life years (QALYs), and costs. The incremental cost-effectiveness ratio (ICER) is then calculated to evaluate the cost-effectiveness of the current vaccination strategy, and both one-way deterministic sensitivity analysis and probabilistic sensitivity analysis (PSA) are applied to assess the impact of uncertainties on results. RESULTS: Our simulation indicates that compared with a no-vaccination scenario, vaccination amongst the general population in mainland China would reduce the infection rate from 100% to 45.3% and decrease the death rate from 6.8% to 3.1%. Consequently, the strategy will lead to a saving of 37,664.77 CNY (US$5,256.70) and a gain of 0.50 QALYs per person per year on average (lifetime QALY and productivity loss due to immature death are included). The cost-saving for each QALY gain is 74,895.69 CNY (US$10,452.85). Result of the PSA indicates that vaccination is the dominating strategy with a probability of 97.9%, and the strategy is cost-effective with a probability of 98.5% when the willingness-to-pay (WTP) is 72,000 CNY (US$10,048.71) per QALY. CONCLUSION: Compared with a no-vaccination scenario, vaccination among the general population in mainland China is the dominating strategy from a societal perspective. The conclusion is considered robust in the sensitivity analyses. |
format | Online Article Text |
id | pubmed-10027744 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100277442023-03-22 Cost-effectiveness analysis of vaccination against COVID-19 in China Zhou, Huixuan Ding, Ningxin Han, Xueyan Zhang, Hanyue Liu, Zeting Jia, Xiao Yu, Jingjing Zhang, Wei Front Public Health Public Health INTRODUCTION: Since September 2020, Chinese populations aged > 3 years have been encouraged to receive a two-dose inoculation with vaccines against coronavirus disease 2019 (COVID-19). This study aims to evaluate the cost-effectiveness of the current vaccination strategy amongst the general population in mainland China from a societal perspective. METHODS: In this study, we construct a decision tree with Markov models to compare the economic and health consequences of the current vaccination strategy versus a no-vaccination scenario, over a time horizon of one year and an annual discount rate of 5%. Transition probabilities, health utilities, healthcare costs, and productivity losses are estimated from literature. Outcome measures include infection rates, death rates, quality-adjusted life years (QALYs), and costs. The incremental cost-effectiveness ratio (ICER) is then calculated to evaluate the cost-effectiveness of the current vaccination strategy, and both one-way deterministic sensitivity analysis and probabilistic sensitivity analysis (PSA) are applied to assess the impact of uncertainties on results. RESULTS: Our simulation indicates that compared with a no-vaccination scenario, vaccination amongst the general population in mainland China would reduce the infection rate from 100% to 45.3% and decrease the death rate from 6.8% to 3.1%. Consequently, the strategy will lead to a saving of 37,664.77 CNY (US$5,256.70) and a gain of 0.50 QALYs per person per year on average (lifetime QALY and productivity loss due to immature death are included). The cost-saving for each QALY gain is 74,895.69 CNY (US$10,452.85). Result of the PSA indicates that vaccination is the dominating strategy with a probability of 97.9%, and the strategy is cost-effective with a probability of 98.5% when the willingness-to-pay (WTP) is 72,000 CNY (US$10,048.71) per QALY. CONCLUSION: Compared with a no-vaccination scenario, vaccination among the general population in mainland China is the dominating strategy from a societal perspective. The conclusion is considered robust in the sensitivity analyses. Frontiers Media S.A. 2023-03-07 /pmc/articles/PMC10027744/ /pubmed/36960359 http://dx.doi.org/10.3389/fpubh.2023.1037556 Text en Copyright © 2023 Zhou, Ding, Han, Zhang, Liu, Jia, Yu and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Public Health Zhou, Huixuan Ding, Ningxin Han, Xueyan Zhang, Hanyue Liu, Zeting Jia, Xiao Yu, Jingjing Zhang, Wei Cost-effectiveness analysis of vaccination against COVID-19 in China |
title | Cost-effectiveness analysis of vaccination against COVID-19 in China |
title_full | Cost-effectiveness analysis of vaccination against COVID-19 in China |
title_fullStr | Cost-effectiveness analysis of vaccination against COVID-19 in China |
title_full_unstemmed | Cost-effectiveness analysis of vaccination against COVID-19 in China |
title_short | Cost-effectiveness analysis of vaccination against COVID-19 in China |
title_sort | cost-effectiveness analysis of vaccination against covid-19 in china |
topic | Public Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027744/ https://www.ncbi.nlm.nih.gov/pubmed/36960359 http://dx.doi.org/10.3389/fpubh.2023.1037556 |
work_keys_str_mv | AT zhouhuixuan costeffectivenessanalysisofvaccinationagainstcovid19inchina AT dingningxin costeffectivenessanalysisofvaccinationagainstcovid19inchina AT hanxueyan costeffectivenessanalysisofvaccinationagainstcovid19inchina AT zhanghanyue costeffectivenessanalysisofvaccinationagainstcovid19inchina AT liuzeting costeffectivenessanalysisofvaccinationagainstcovid19inchina AT jiaxiao costeffectivenessanalysisofvaccinationagainstcovid19inchina AT yujingjing costeffectivenessanalysisofvaccinationagainstcovid19inchina AT zhangwei costeffectivenessanalysisofvaccinationagainstcovid19inchina |